Are GLP-1 agonists a quick fix for weight loss or a lifetime prescription? GLP-1 and dual GIP/GLP-1 receptor agonists are a class of medications that are used to treat type II diabetes mellitus and/or obesity. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are indicated in type 2 diabetes and obesity for their high efficacy in controlling glycaemia and inducing body weight loss, respectively. GLP-1 receptor agonists have been shown in clinical trials to effectively lower blood glucose levels, promote weight loss, and improve cardiovascular outcomes in individuals with diabetes. This has led to the development of GLP-1 receptor agonist medications, which are used to manage type 2 diabetes by promoting insulin secretion and lowering blood glucose levels. GLP-1 also suppresses secretion of glucagon from α cell of pancreas and concentration of glucose in blood after meal. GLP-1 is known as incretin as same as GIP (Glucose-dependent Insulinotropic Polypeptide), it promotes secretion of insulin from β cells of the isles of Langerhans in the pancreas as glucose dependently.

"Ozempic helps regulate blood glucose by stimulating the pancreas to release more insulin when blood glucose levels are elevated. The ARC is in close proximity to the deficient blood-brain barrier of the median eminence of the hypothalamus, thus allowing this region to respond rapidly to the release of a gut hormone into the circulation. These recommendations may prevent people with T2D and/or obesity from withdrawing from GLP-1 RAs treatment, thus benefitting from their superior effect on glycaemic control and weight loss. Healthcare professionals only recommend injectable diabetes drugs for weight loss for people who either have obesity or overweight and another weight-related medical condition. People will need to be obese or overweight and have at least one weight-related health condition to use GLP-1 medications. GLP-1 drugs can reduce the need for CPAP machines as patients lose weight and improve their breathing. "Some patients respond incredibly well, and others don’t. That’s been a very successful pathway for us, and hopefully that means that we get these therapies to the patients who need them in a much more timely and standard fashion. Despite their popularity on social media, these medications carry significant risks and can be harmful to those who do not need them.

Do I still need to exercise or eat in a particular way when I am GLP-1 medications for weight loss? In fact I am still solidly in the red when It comes to this site. The significant decline of somatostatin compared with baseline after GLP-1 stimulated somatostatin maximally was observed newly and additional research is needed in the future to prove that the fact might be associated with insulinotrophic action of GLP-1. Research from 2023 shows that semaglutide, such as Ozempic and Wegovy, and tirzepatide, such as Mounjaro and Zepbound, are more effective than liraglutide for weight loss. Some drugs, such as those containing semaglutide and tirzepatide, are more effective than others. Rodent studies have also shown that semaglutide, tirzepatide, and liraglutide can cause thyroid C-cell tumors. Health experts do not yet know whether these injectable diabetes drugs can cause tumors in humans, but it is important to understand the risk. Background Primary polydipsia, characterized by excessive fluid intake, carries the risk of water intoxication and hyponatremia, but treatment options are scarce. An expert panel comprising endocrinologists, nephrologists, primary care physicians, cardiologists, internists and diabetes nurse educators convened across virtual meetings to reach a consensus regarding these compelling recommendations. More recently, in 2024, the FDA approved Wegovy (semaglutide) for fiber-based appetite support use in the prevention of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease, with or without type 2 diabetes.

These innovative treatments work in harmony with your body to help you achieve and maintain a healthy weight-giving you more control over your health and wellness journey. Fact: They also improve insulin sensitivity, slow gastric emptying, and help regulate blood sugar levels. These drugs slow digestion, help control blood sugar, and reduce appetite. Drug of type 2 diabetes has been developed by utilizing the functional mechanism of GLP-1 such as blood sugar control through pancreas, delayed gastric emptying and fiber-based appetite support suppression which contributes weight loss as extra-pancreatic effects. In the largest-ever genetic study exploring how genes affect blood sugar levels and health outcomes, researchers concluded that lung disorders should now be considered a complication of type 2 diabetes. Researchers gave the 17,604 participants a placebo or Wegovy. Researchers tested the drug on patients with established CVD and CV risk factor subgroups. The results showed that Wegovy reduced the risk of MACE in 6.5% of participants who took Wegovy, compared to 8% of adults who took the placebo. In 2020 the FDA approved Trulicity (dulaglutide) for the reduction of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.